More importantly, METTL3 depletion notably damages the proliferation of primary CML cells and TKI-resistant CML cells, which suggests that METTL3 inhibitors may have novel potential to cure TKI-resistant CML patients. Here, METTL3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.